164 related articles for article (PubMed ID: 24063766)
1. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
Chiorean R; Braicu C; Berindan-Neagoe I
Breast; 2013 Dec; 22(6):1026-33. PubMed ID: 24063766
[TBL] [Abstract][Full Text] [Related]
2. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
3. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
4. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
5. Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
Dawood S; Gonzalez-Angulo AM
Cancer Biomark; 2012-2013; 12(6):241-50. PubMed ID: 23735944
[TBL] [Abstract][Full Text] [Related]
6. Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A; Ferrer NI; Ciruelos E; López-Vacas R; Martínez FG; Espinosa E; Vara JÁ
Proteomics Clin Appl; 2013 Apr; 7(3-4):283-91. PubMed ID: 23436753
[TBL] [Abstract][Full Text] [Related]
7. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as regulatory elements in triple negative breast cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
Cancer Lett; 2014 Nov; 354(1):1-4. PubMed ID: 25107641
[TBL] [Abstract][Full Text] [Related]
9. Significance of biomarker discordance in breast cancer from the pathologist's perspective.
Gong Y
Cancer Biomark; 2012-2013; 12(6):207-18. PubMed ID: 23735941
[TBL] [Abstract][Full Text] [Related]
10. Extended adjuvant chemotherapy in endocrine non-responsive disease.
Colleoni M; Munzone E
Breast; 2013 Aug; 22 Suppl 2():S161-4. PubMed ID: 24074780
[TBL] [Abstract][Full Text] [Related]
11. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast carcinoma: current and emerging concepts.
Schmadeka R; Harmon BE; Singh M
Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: investigating potential molecular therapeutic target.
Papa A; Caruso D; Tomao S; Rossi L; Zaccarelli E; Tomao F
Expert Opin Ther Targets; 2015 Jan; 19(1):55-75. PubMed ID: 25307277
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry for Triple-Negative Breast Cancer.
Naidoo K; Pinder SE
Methods Mol Biol; 2016; 1406():39-51. PubMed ID: 26820943
[TBL] [Abstract][Full Text] [Related]
15. Subtyping of triple-negative breast cancer.
Mayer IA
Clin Adv Hematol Oncol; 2013 Nov; 11(11):731-2. PubMed ID: 24896546
[No Abstract] [Full Text] [Related]
16. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
18. Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway.
Yang B; Huang J; Xiang T; Yin X; Luo X; Huang J; Luo F; Li H; Li H; Ren G
J Appl Toxicol; 2014 Jan; 34(1):105-12. PubMed ID: 24122885
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: molecular subtypes and targeted therapy.
Hirshfield KM; Ganesan S
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
[TBL] [Abstract][Full Text] [Related]
20. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
